Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.430
+0.060 (1.78%)
At close: Jun 9, 2026, 4:00 PM EDT
3.370
-0.060 (-1.75%)
Pre-market: Jun 10, 2026, 8:11 AM EDT
Voyager Therapeutics Employees
Voyager Therapeutics had 141 employees as of December 31, 2025. The number of employees decreased by 31 or -18.02% compared to the previous year.
Employees
141
Change (1Y)
-31
Growth (1Y)
-18.02%
Revenue / Employee
$258,823
Profits / Employee
-$827,213
Market Cap
207.25M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 141 | -31 | -18.02% | 141 | 0 |
| Dec 31, 2024 | 172 | 10 | 6.17% | 172 | 0 |
| Dec 31, 2023 | 162 | 37 | 29.60% | 162 | 0 |
| Dec 31, 2022 | 125 | 24 | 23.76% | 125 | 0 |
| Dec 31, 2021 | 101 | -78 | -43.58% | 101 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Arcturus Therapeutics Holdings | 111 |
| Keros Therapeutics | 87 |
| Cybin | 50 |
| Camp4 Therapeutics | 48 |
| ALX Oncology Holdings | 43 |
| Whitehawk Therapeutics | 23 |
| Q32 Bio | 22 |
VYGR News
- 8 days ago - Voyager Therapeutics announces FDA clearance for VY1706 IND application - TheFly
- 9 days ago - Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease - GlobeNewsWire
- 4 weeks ago - Voyager Therapeutics presents GLP for toxicology data for VY1706 - TheFly
- 4 weeks ago - Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 - GlobeNewsWire
- 4 weeks ago - Voyager Therapeutics reports Q1 EPS (47c), consensus (53c) - TheFly
- 4 weeks ago - Voyager Reports First Quarter 2026 Financial and Operating Results - GlobeNewsWire
- 4 weeks ago - Voyager Therapeutics Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Voyager Therapeutics Earnings release: Q1 2026 - Filings